Mental health service use in a national sample of college students with co-occurring depression or anxiety and substance use.

Drug Alcohol Depend Rep

Heller School for Social Policy and Management, Institute for Behavioral Health, Brandeis University, 415 South Street, Waltham, MA 02453, USA.

Published: March 2022

Introduction: Campus health systems can provide timely and accessible resources for students with co-occurring substance use and mental illness, but little is known about the degree to which students use these systems. This study examined mental health service utilization among students with symptoms of anxiety or depression, stratified by substance use.

Methods: This cross-sectional study used data came from the 2017-2020 Healthy Minds Study. Mental health service use was examined among students with clinically significant anxiety or depression ( = 65,969), stratified by substance use type (no use, alcohol or tobacco use, marijuana use, other drug use). We performed a series of weighted logistic regressions to assess the adjusted association of substance use type with past year use of campus, off-campus outpatient, emergency department, and hospital mental health services.

Results: Among students, 39.3% reported exclusive use of alcohol or tobacco, 22.9% reported use of marijuana, and 5.9% reported use of other drugs. Use of alcohol or tobacco was not associated with mental health service utilization, while students who use marijuana faced increased odds of campus (OR 1.10, 95% CI 1.01, 1.20) and off-campus outpatient mental health service utilization (OR 1.27, 95% CI 1.17, 1.37). Other drug use was associated with increased odds of off-campus outpatient (OR 1.28, 95% CI 1.14, 1.48), emergency department (OR 2.13, 95% CI 1.50, 3.03) and hospital service utilization (OR 1.52, 95% CI 1.13, 2.04).

Conclusions: Universities should consider screening for substance use and common mental illnesses to support the health of high-risk students.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948943PMC
http://dx.doi.org/10.1016/j.dadr.2022.100025DOI Listing

Publication Analysis

Top Keywords

mental health
24
health service
20
service utilization
16
alcohol tobacco
12
off-campus outpatient
12
mental
8
students
8
students co-occurring
8
utilization students
8
anxiety depression
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AIMST University, Bedong, Kedah, Malaysia.

Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.

View Article and Find Full Text PDF

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.

Background: Some types of cancer have been associated with reduced risk of clinical dementia diagnosis. Whether cancer history may be associated with neuropathological features of neurodegeneration or cerebrovascular disease is not well understood. We investigated the relation between cancer diagnosis and brain pathology in a sample of community-based research volunteers enrolled in an Alzheimer's Disease Research Center (ADRC) cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!